

# CITERON 1

## Instructions on medical use of medicinal facilities

**Trade name of the drug:** Citeron 1.

**International nonproprietary name:** Hyaluronic acid + citicoline.

**Dosage form:** Sterile eye drops, 10 ml.

**Product description:** Transparent, colorless solution.

**Pharmacotherapeutic group:** Ophthalmic neuroprotector.

**Compound:**

hyaluronic acid 0.2%, citicoline monosodium salt 2%, sodium phosphate monohydrate, sodium dihydrogen phosphate dodecahydrate, sodium chloride, benzalkonium chloride, water for injection.

**Pharmacological properties:**

*Pharmacodynamics:* Citeron 1 is ophthalmic solution containing 0.2% hyaluronic acid with high molecular weight obtained by biotechnological synthesis. Hyaluronic acid is added to mucomimetic, mucoadhesive and viscoelastic solutions, useful in improving the stability of the tear film and thus keeping the ocular surface lubricated, hydrated and protected. In addition, solutions containing hyaluronic acid can create a favorable microenvironment for restoring the ocular surface in cases of damage to the cornea and conjunctival epithelium. The presence of citicoline in Citeron 1 provides beneficial structural support in restoring the integrity of cell membranes damaged due to degenerative ocular pathologies. The moisturizing and protective properties of the product provide relief in case of irritation, burning and foreign body sensation caused by environmental factors or prolonged use of video terminals. Citeron 1 indirectly promotes the physiological processes of corneal reepithelialization after eye surgery, laser application, or small scratches on the corneal surface (for example, in glaucoma).

**Indications for use:**

Local use in ophthalmology. Applicable for:

- Irritation, burning and foreign body sensation caused by factors: wind, sun, dry air, salt water, smoke, bright light, air conditioning, heating, prolonged use of gadgets;
- Using contact lenses;
- Glaucoma and optical glaucoma neuropathy;
- Diabetic retinopathy;
- Ischemic optic neuropathy;
- Macular degeneration;
- Degenerative diseases of the cornea;
- Changes in the fundus of the eye that are associated with hypertension: angiopathy, angiosclerosis, retinopathy;
- Keratitis;
- Changes in the fundus of the eye associated with refractive errors: high myopia, high hyperopia;
- Amblyopia;
- Before and after keratorefractive surgeries: photorefractive keratotomy, LASIK, etc.

**Mode of application:**

1 drop 2-3 times a day as needed. The recommended course of treatment is 2 months three times a year, or for 4 months twice a year (depending on the stage of the disease).

**Side effect:**

Temporary blurred vision may occur after using the drug. It is recommended to wait a few seconds before starting any activity that requires clear vision.

**Contraindications:**

- Individual intolerance to components.

**Precautionary measures:**

- Do not use if the packaging is damaged;
- Do not use if you are intolerant to any component of the drug;
- Do not use after the expiration date indicated on the package;
- Avoid contact of the dropper with the surface of the eye;
- It is necessary to wait 10-15 minutes after using the drops before using other ophthalmic agents for topical use;
- Use no more than 30 days after opening the package;
- Keep out of the reach of children;
- For external ophthalmic use only.

**Release form:**

Sterile eye drops, 10 ml.

**Storage conditions:**

Store at a temperature not exceeding 25 °C.

**Best before date:**

3 years. No more than 30 days after opening the package.

Do not use after the expiration date! Sterile.

**Vacation conditions:**

Over the counter.

**Made for:**

**MAXX - PHARM LTD**

**London, Great Britain**

